1-3 of 3
Francesca Ferrante
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A - BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII

Steven W. Pipe, MD, Francesca Ferrante, MD, Muriel Reis, Sara Wiegmann, Claudia Lange, Manuela Braun, Lisa A Michaels
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-139803
Published: 2020
Journal Articles

Clinical Outcomes in Adults/Adolescents with Hemophilia B Treated Long Term with Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis: Interim Results of the B-Yond Extension Study

Tadashi Matsushita, Johnny Mahlangu, Amy D Shapiro, K John Pasi, Margaret V. Ragni, MD, Margareth C Ozelo, Johannes Oldenburg, Prof, Ross I Baker, Huixing Yuan, Alejandra Ramirez-Santiago, Francesca Ferrante, Stefan Lethagen
Journal: Blood
Blood (2016) 128 (22): 1416.
https://doi.org/10.1182/blood.V128.22.1416.1416
Published: 2016
Journal Articles

Long Term Safety and Efficacy of Recombinant Factor IX Fc Fusion Protein (rFIXFc) Prophylaxis in Children with Hemophilia B: Interim Results of the B-Yond Extension Study

Jonathan M. Ducore, Kathelijn Fischer, Roshni Kulkarni, MD, Beatrice Nolan, Carolyn M. Bennett, David J Perry, Huixing Yuan, Alejandra Ramirez-Santiago, Francesca Ferrante, Stefan Lethagen
Journal: Blood
Blood (2016) 128 (22): 4976.
https://doi.org/10.1182/blood.V128.22.4976.4976
Published: 2016